The Gastrointestinal Oncology Program Is a comprehensive program in gastrointestinal cancer research encompassing basic research, clinical and translational research. The program consists of 39 members from 9 different departments and two schools within the University of Michigan, receiving $9 million in annual direct support, Including $4.4 in NCI funding. The GI grant portfolio includes a $2.1 M SPORE grant to study colorectal and pancreatic cancer, two PO1 grants, U01 and U19 grants. The program is focused on the development of fundamental basic research into the causes and prevention of human gastrointestinal cancers and translational studies applying these research findings to improve the early and accurate diagnosis, evaluation, and therapeutic approaches to gastrointestinal cancer as well as Issues related to health quality outcomes, The basic research alms of the Gastrointestinal Oncology Program focus on mechanisms of cell growth and differentiation, stem cells and cell metastasis. The clinical research focuses on neoadjuvant therapies and biomarkers. The outcome research focuses on health care quality Issues. Nine new program members recruited over this grant period include Drs Marwan Fakih, Weiping Zou, Grace Chen, Chandan Kumar, Marina Pasca Di Magliano, Patrick Hu, Gazala Khan, Theodore Welling, and John Carethers. This program, which was rated as

Public Health Relevance

The GI Oncology Program is dedicated to providing state-of-the art clinical care of patients with neoplasms of the GI tract in a multidisciplinary setting. This allows optimal tumor treatment based on input from multiple disciplines, Including surgery, medical and radiation oncology, gastroenterology, and interventional radiology. The GI oncology program also has a major focus on basic and translational research to develop a more effective approach to cancer prevention and the development of novel, more effective therapeutics.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Ann Arbor
United States
Zip Code
Lee, Alice W; Ness, Roberta B; Roman, Lynda D et al. (2016) Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. Obstet Gynecol 127:828-36
Mathewson, Nathan D; Jenq, Robert; Mathew, Anna V et al. (2016) Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat Immunol 17:505-13
Owen, John Henry; Graham, Martin P; Chinn, Steven B et al. (2016) Novel method of cell line establishment utilizing fluorescence-activated cell sorting resulting in 6 new head and neck squamous cell carcinoma lines. Head Neck 38 Suppl 1:E459-67
Peng, Dongjun; Tanikawa, Takashi; Li, Wei et al. (2016) Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling. Cancer Res 76:3156-65
Kadakia, Kunal C; Snyder, Claire F; Kidwell, Kelley M et al. (2016) Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer. Oncologist 21:539-46
Boonstra, Philip S; Mukherjee, Bhramar; Gruber, Stephen B et al. (2016) Tests for Gene-Environment Interactions and Joint Effects With Exposure Misclassification. Am J Epidemiol 183:237-47
Amin, Nisar A; Malek, Sami N (2016) Gene mutations in chronic lymphocytic leukemia. Semin Oncol 43:215-21
Hardiman, Karin M; Ulintz, Peter J; Kuick, Rork D et al. (2016) Intra-tumor genetic heterogeneity in rectal cancer. Lab Invest 96:4-15
Boonstra, Philip S; Taylor, Jeremy M G; Smolska-Ciszewska, Beata et al. (2016) Alpha/beta (α/β) ratio for prostate cancer derived from external beam radiotherapy and brachytherapy boost. Br J Radiol 89:20150957
Di Girolamo, Daniela; Ambrosio, Raffaele; De Stefano, Maria A et al. (2016) Reciprocal interplay between thyroid hormone and microRNA-21 regulates hedgehog pathway-driven skin tumorigenesis. J Clin Invest 126:2308-20

Showing the most recent 10 out of 1165 publications